EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The silent pharmacist: Harnessing the gut microbiome to improve therapy in hematologic malignancies

Amr Ali Mohamed Abdelgawwad El-Sehrawy, Hamed Soleimani Samarkhazan

Translational Oncology · 2026-08 · 70 · 102833

DOI: 10.1016/j.tranon.2026.102833 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Translational Oncology, 2026-08. Verfasst von Amr Ali Mohamed Abdelgawwad El-Sehrawy und 1 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, Diabetes, Endocrinology and Metabolism, Mansoura University, Mansoura, Egypt. Electronic address: sehrawyamr@gmail.com. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gut microbiome, a complex ecosystem of microorganisms, is now recognized as a key determinant of drug efficacy and toxicity, giving rise to the field of pharmacomicrobiomics. This review decodes the profound influence of the gut microbiome on treatment outcomes for hematologic malignancies. We explore the tripartite mechanistic pathways through which gut microbes act: the direct enzymatic biotransformation of chemotherapeutic agents, the indirect immunomodulation of systemic and anti-tumor responses, and the preservation of mucosal barrier integrity to prevent devastating complications like graft-versus-host disease (GVHD). The manuscript details how the microbiome interacts with specific drug classes, from conventional chemotherapies like cyclophosphamide to cutting-edge immunotherapies like immune checkpoint inhibitors and CAR-T cells, shaping their clinical success. Furthermore, we discuss the translational potential of targeting this "silent pharmacist" through fecal microbiota transplantation, next-generation probiotics, and dietary interventions. Finally, we highlight the main translational opportunities, current limitations, and future clinical priorities for integrating microbiome science into hematology, paving the way for more personalized and improved cancer care.

Schlagwörter

Stichwörter der Autor:innen

Gut microbiomeHematologic malignanciesImmunotherapyPersonalized medicinePharmacomicrobiomics

Autor:innen und Institutionen

  • Internal Medicine, Diabetes, Endocrinology and Metabolism, Mansoura University, Mansoura, Egypt. Electronic address: sehrawyamr@gmail.com.
  • Student Research Committee, Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: Hamed.soleimani.s@gmail.com.

Zitieren

APA

El-Sehrawy, A. A. M. A., & Soleimani Samarkhazan, H. (2026). The silent pharmacist: Harnessing the gut microbiome to improve therapy in hematologic malignancies. Translational Oncology, 70, 102833. https://doi.org/10.1016/j.tranon.2026.102833

Vancouver

El-Sehrawy AAMA, Soleimani Samarkhazan H. The silent pharmacist: Harnessing the gut microbiome to improve therapy in hematologic malignancies. Translational Oncology. 2026;70:102833. doi:10.1016/j.tranon.2026.102833

BibTeX
@article{ElSehrawy2026,
  author = {El-Sehrawy, Amr Ali Mohamed Abdelgawwad and Soleimani Samarkhazan, Hamed},
  title = {The silent pharmacist: Harnessing the gut microbiome to improve therapy in hematologic malignancies},
  journal = {Translational Oncology},
  year = {2026},
  volume = {70},
  pages = {102833},
  doi = {10.1016/j.tranon.2026.102833}
}
Kostenlos starten →